Pitviper Envenomation Guidelines Should Address Choice between FDA-approved Treatments for Cases at Risk of Late Coagulopathy

Leslie V. Boyer; Anne Michelle Ruha

doi:10.1016/j.wem.2015.10.013

Pitviper Envenomation Guidelines Should Address Choice between FDA-approved Treatments for Cases at Risk of Late Coagulopathy

Leslie V. Boyer, Anne Michelle Ruha

Viper Institute

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	341-342
Number of pages	2
Journal	Wilderness and Environmental Medicine
Volume	27
Issue number	2
DOIs	https://doi.org/10.1016/j.wem.2015.10.013
State	Published - Jun 1 2016

ASJC Scopus subject areas

Emergency Medicine
Public Health, Environmental and Occupational Health

Access to Document

10.1016/j.wem.2015.10.013

Cite this

@article{6ed4a723396e43558eec671409cf097d,

title = "Pitviper Envenomation Guidelines Should Address Choice between FDA-approved Treatments for Cases at Risk of Late Coagulopathy",

author = "Boyer, {Leslie V.} and Ruha, {Anne Michelle}",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.wem.2015.10.013",

language = "English (US)",

volume = "27",

pages = "341--342",

journal = "Wilderness and Environmental Medicine",

issn = "1080-6032",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Pitviper Envenomation Guidelines Should Address Choice between FDA-approved Treatments for Cases at Risk of Late Coagulopathy

AU - Boyer, Leslie V.

AU - Ruha, Anne Michelle

PY - 2016/6/1

Y1 - 2016/6/1

UR - http://www.scopus.com/inward/record.url?scp=84962877586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962877586&partnerID=8YFLogxK

U2 - 10.1016/j.wem.2015.10.013

DO - 10.1016/j.wem.2015.10.013

M3 - Letter

C2 - 27079732

AN - SCOPUS:84962877586

SN - 1080-6032

VL - 27

SP - 341

EP - 342

JO - Wilderness and Environmental Medicine

JF - Wilderness and Environmental Medicine

IS - 2

ER -

Pitviper Envenomation Guidelines Should Address Choice between FDA-approved Treatments for Cases at Risk of Late Coagulopathy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this